Myasthenia Gravis Market by Diagnosis (Edrophonium Tests, Blood Tests, Pulmonary Function Tests, Electrodiagnostic, Imaging, and Others), by Treatment (Surgery, Medication, Plasmapheresis and Intravenous Immunoglobulin, Autologous Hematopoietic Stem Cell Transplantation (HSCT), and others), and by End-User (Hospitals, Academic Research Institutes, Clinics, and Others)-Global Industry Analytics, COVID-19 Business Impact, and Trends, 2020–2029

                                          
Abstract
                    
The report covers a forecast and an analysis of the myasthenia gravis market on a global and regional level. The study provides historical data for 2016, 2017, and 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints of the myasthenia gravis market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the myasthenia gravis market on a global level.

In order to give the users of this report a comprehensive view of the myasthenia gravis market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.


The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new technology launch, agreements, partnerships, collaborations & joint ventures, R&D, and regional expansion of major participants involved in the market on a global and regional basis. Moreover, the study covers price trend analysis and product portfolio of various companies according to regions.

The study provides a decisive view of the myasthenia gravis market based on diagnosis, treatment, end-user, and region. All the segments have been analyzed based on present and future trends in the market are estimated from 2019 to 2025. By diagnosis, the market is segmented into edrophonium tests, blood tests, pulmonary function tests, electrodiagnostic, imaging, and others. By treatment, the market is segmented into surgery, medication, plasmapheresis and intravenous immunoglobulin, autologous hematopoietic stem cell transplantation (HSCT), and others. By end-user, the market is segmented into hospitals, academic research institutes, clinics, and others.

The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further divided into major countries including the U.S., Canada, Germany, France, UK, Brazil, China, Japan, India, and Brazil.

Some key players of the global myasthenia gravis market are Novartis Pharmaceuticals Corporation, AbbVie Inc., Biogen Inc., Pfizer, Valeant Pharmaceuticals International, Bristol-Myers Squibb Company, F. Hoffmann Roche La Ltd., GlaxoSmithKline, RPG Life Sciences, and Grifols SA, among others.

This report segments the global myasthenia gravis market as follows:

Global Myasthenia Gravis Market: Diagnosis Analysis

	Edrophonium Tests
	Blood Tests
	Pulmonary Function Tests
	Electrodiagnostic
	Imaging
	Others

Global Myasthenia Gravis Market: Treatment Analysis

	Surgery
	Medication
	Plasmapheresis and Intravenous Immunoglobulin
	Autologous Hematopoietic Stem Cell Transplantation (HSCT)
	Others

Global Myasthenia Gravis Market: End-User Analysis

	Hospitals
	Academic Research Institutes
	Clinics
	Other

Global Myasthenia Gravis Market: Regional Analysis

	North America
	
		The U.S.
	
	
	Europe
	
		UK
		France
		Germany
	
	
	Asia Pacific
	
		China
		Japan
		India
	
	
	Latin America
	
		Brazil
	
	
	Middle East and Africa